Skip to content
Tissue and Cell Culture Reagents Online

Tissue and Cell Culture Reagents Online

Fbs, Bsa, Fetal Bovine Serum for primary cells

Menu
  • Home
  • ELISA KITS
  • ANTIBODY
  • RNA
  • DNA
  • Culture
  • Distributors
  • Contact Us
Menu
Panbio

Antigen and Molecular Tests for COVID-19

Posted on December 17, 2021December 21, 2021 by Jack

The diagnostic testing field for COVID-19 is rapidly evolving, with many tests focused on diagnosing patients with active viral infections. Diagnostics able to detect current, active infections are typically antigen- and molecular-based tests. These tests inform researchers and health providers of the presence of the pathogen, either by amplifying and detecting its genetic material or identifying unique markers of the pathogen itself. The viral genomic material for SARS-CoV-2 is ribonucleic acid (RNA), which remains in the body only while the virus is still replicating, even at very low levels.

Antigen tests detect specific viral proteins (antigens) present in a patient sample taken using nasal or nasopharyngeal swabs and can provide results in under a half hour. Antigens are found on the surface of the virus particle, which are also shed in patient tissues. These rapid tests detect basic levels of antigen already present in a sample, providing only a simple “yes” or “no,” similar to a pregnancy test.

Molecular tests called nucleic acid amplification tests (NAAT) rely on amplification of existing genetic material in the sample. NAATs include the polymerase chain reaction (PCR) assay in a laboratory to amplify viral genomic material for detection and can provide results in hours to days; other techniques include LAMP and next generation sequencing. These tests require samples from the patient that are likely to contain virus.

 

Most samples are collected using nasopharyngeal swabs or a sputum cup, although the virus may also be detected in feces, urine, or blood. For diseases that are primarily respiratory in nature, like COVID-19, nasopharyngeal swabs have been the most reliable, as they sample an area of the respiratory tract where the virus appears to first infect an individual. This site is relatively easily accessed, compared to the final site of viral infection: the lower respiratory tract. The nasopharyngeal tract likely has (1) active virus replication and (2) enough virus to be detected in test kits.

Many tests now available or in development can use saliva or nasal swabs that facilitate easier sampling procedures for healthcare providers and patients.

For information on serology (antibody) tests, visit our serology tracker or visit our report outlining the needs of a national serology strategy.

 

Disclaimer

This page is updated twice weekly and includes only tests that have received EUA either from commercial manufacturers or laboratory-developed tests. This website is not intended to be used as a reference for funding or grant proposals. Noninclusion in this list should not be interpreted as a judgment on the validity or legitimacy of tests.

If you are a manufacturer or research institution that has an EUA-approved antigen or molecular test that is not yet listed, please submit your information here. Submission of this form does not guarantee inclusion on the website.

 

Note on sensitivity and specificity data

Where available, we list the manufacturer-reported sensitivity and specificity data. A highly sensitive test should capture all true positive results. A highly specific test should rule out all true negative results. These measures are not independently validated by the Johns Hopkins Center for Health Security. If sensitivity or specificity is not listed, it was not available from the manufacturer at the time of posting. When available, the number of samples used for sensitivity/specificity definitions are listed in the product description.

The terms “sensitivity” and “specificity” may not appear in the manufacturers’ information sheets, but are often reported as “positive percent agreement” and “negative percent agreement.“ Sensitivity may also be measured by calculating the limit of detection, which is the lowest detectable number of virus copies in a sample at which the test will return a positive result at least 95% of the time.

Essentially, a lower limit of detection indicates a more sensitive test, with fewer viral copies per sample necessary to elicit a positive test result. The US FDA recommends that manufacturers use these terms to indicate that a nonreference standard was used when evaluating the test.

 

More information on molecular tests:

  • How do molecular tests detect SARS-CoV-2?
  • Common types of antigen and molecular tests being developed for SARS-CoV-2
  • What kind of antigen and molecular tests are on the market? What’s the difference between them?

 

Tests That Can Be Used for Point-of-Care and Rapid SARS-CoV-2 Testing

Refer to the U.S. Food and Drug Administration (FDA) website for a list of the SARS-CoV-2 point-of-care and rapid tests that have received Emergency Use Authorization (EUA)external icon. Tests that have been authorized for use in a point-of-care setting will have a W, for Waived, in the Authorized Settings column of the FDA table. The laboratory or testing site must use a test authorized for point-of-care use by the FDA and must follow the manufacturer’s instructions for each test.

The instructions for use provide specific information on how to perform the test, which specimens can be used, and the people who may be tested. All of the FDA-authorized tests for current SARS-CoV-2 infection are for use on symptomatic people. However, CMS has indicatedpdf iconexternal icon that CLIA will temporarily allow CLIA-certified laboratories and other testing sites to use SARS-CoV-2 point-of-care and rapid antigen tests on asymptomatic people for the duration of the COVID-19 public health emergency.

 

Reporting Requirements for Point-Of-Care and Rapid Testing

A CLIA-certified laboratory or testing site must report all SARS-CoV-2 diagnostic and screening test results for current or past infections to the person who was tested or that person’s healthcare provider. Depending on the test manufacturer’s instructions for use, which can be found on FDA’s EUA websiteexternal icon, the laboratory or testing site may be required to report a negative test result as a “presumptive negative.”

A CLIA-certified laboratory or testing site must also report all COVID-19 test results to their respective state, tribal, localexternal icon, and territorial health department’s website in accordance with the Coronavirus Aid, Relief, and Economic Security (CARES) Act; refer to the CMS interim final rule for regulatory reporting requirementspdf iconexternal icon. In addition, laboratories and testing sites can find out more about How to Report COVID-19 Laboratory Data.

Panbio
Panbio

 

CMS-certified long-term care (LTC) facilities can submit point-of-care SARS-CoV-2 testing data, including antigen testing data, to CDC’s National Healthcare Safety Network (NHSN). This CDC- and CMS-preferred pathway to submit data to CDC’s NHSN applies only to CMS-certified LTC facilities. Test data submitted to NHSN will be reported to appropriate state and local health departments using standard electronic laboratory messages.

 

Other types of LTC facilities can also report testing data in NHSN for self-tracking or to fulfill state or local reporting requirements, if any. While NHSN is the CDC- and CMS-preferred pathway, Medicare and Medicaid-certified LTC facilities can submit data through the other mechanisms described in the Current Methods of Submission section of HHS Laboratory Reporting Guidancepdf iconexternal icon to meet the reporting requirements.

 

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
« May    

RSS Cell Stem Cell

  • To play Paneth or goblet: Shapeshifting secretory cells read the room
  • Rapid generation of functional vascular organoids via simultaneous transcription factor activation of endothelial and mural lineages
  • An organoid co-culture model for probing systemic anti-tumor immunity in lung cancer
  • Multiomic profiling reveals that prostaglandin E2 reverses aged muscle stem cell dysfunction, leading to increased regeneration and strength
  • Human airway submucosal gland organoids to study respiratory inflammation and infection
  • Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy
  • IGF2BP1 restricts the induction of human primordial germ cell fate in an m6A-dependent manner
  • Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia
  • Establishing dorsal-ventral patterning in human neural tube organoids with synthetic organizers
  • Integrating collecting systems in human kidney organoids through fusion of distal nephron to ureteric bud
  • ANTIBODY
  • blood
  • Camel
  • Chronic exposure to excess iron promotes EMT and cancer via p53 loss in pancreatic cancer.
  • coli recombinant
  • colorimetric
  • colorless
  • Containing
  • Culture
  • DNA
  • ELISA KITS
  • genome
  • GMO
  • Human Cerebrospinal Fluid Induces Neuronal Excitability Changes in Resected Human Neocortical and Hippocampal Brain Slices.
  • Quantitative Imaging of Changes in Astrocytic and Neuronal Adenosine Triphosphate Using Two Different Variants of ATeam.
  • Resolvin E1 in Follicular Fluid Acts as a Potential Biomarker and Improves Oocyte Developmental Competence by Optimizing Cumulus Cells.
  • RNA
  • Sheep
  • Targeting PIK3CG in Combination with Paclitaxel as a Potential Therapeutic Regimen in Claudin-Low Breast Cancer.
  1. A WordPress Commenter on Hello world!February 28, 2020

    Hi, this is a comment. To get started with moderating, editing, and deleting comments, please visit the Comments screen in…

Recent Posts

  • Cell Culture Media Overview
  • Discover AffiMEDIUM, the New Product Line for Culture Medium
  • Capilia Rapid Antigen
  • Compare antibodies lab reagents for research
  • Compare recombinant lab reagents for research

  • ANTIBODY
  • blood
  • Camel
  • Chronic exposure to excess iron promotes EMT and cancer via p53 loss in pancreatic cancer.
  • coli recombinant
  • colorimetric
  • colorless
  • Containing
  • Culture
  • DNA
  • ELISA KITS
  • genome
  • GMO
  • Human Cerebrospinal Fluid Induces Neuronal Excitability Changes in Resected Human Neocortical and Hippocampal Brain Slices.
  • Quantitative Imaging of Changes in Astrocytic and Neuronal Adenosine Triphosphate Using Two Different Variants of ATeam.
  • Resolvin E1 in Follicular Fluid Acts as a Potential Biomarker and Improves Oocyte Developmental Competence by Optimizing Cumulus Cells.
  • RNA
  • Sheep
  • Targeting PIK3CG in Combination with Paclitaxel as a Potential Therapeutic Regimen in Claudin-Low Breast Cancer.
  • Cell Culture Media Overview
  • Discover AffiMEDIUM, the New Product Line for Culture Medium
  • Capilia Rapid Antigen
  • Compare antibodies lab reagents for research
  • Compare recombinant lab reagents for research
© 2025 Tissue and Cell Culture Reagents Online | Powered by Superbs Personal Blog theme